Objective: To investigate the relationship between immunohistochemical characteristics and recurrence after complete remission (CR) with fertility preservation treatment in patients with endometrial cancer (EC) and endometrial atypical hyperplasia (AH).
Methods: The clinical data and immunohistochemical results of 53 patients with EC and 68 patients with AH admitted to Peking University People's Hospital from January 2010 to January 2021 were retrospectively analyzed. Patients were divided into two groups according to whether recurrence after complete remission (CR): group 1: recurrence after CR; group 2: no recurrence after CR, for statistical analysis.
Results: (1) The expression rate of ER in group 1 was lower than that in group 2, (P < 0.05). The expression rate of Ki-67 in group 1 was significantly higher than that in group 2, (P < 0.01). The expression rates of PR, P16, P53, and PTEN were not significantly different between the two groups (P > 0.05); (2) combination index ER/ Ki-67 row ROC curve analysis, there was a significant difference (P < 0.01), the best cut-off value was 3.55, sensitivity 0.730, specificity 1.000, Youden index 0.730. The 3-year RFS of high rate patients was 100%, and that of low rate patients was 42.3%, P < 0.01.
Conclusions: The expression rate of Ki-67 is of great significance in predicting the recurrence of EC after fertility preservation therapy. The best cut-off value of combination index ER/ Ki-67 (3.55) was better than a single immunohistochemical marker in predicting recurrence of EC after fertility preservation treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00404-022-06398-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Kyphoplasty (KP) is a well-established procedure with a low complication risk, however, the procedure's safety in patients with comorbidities and in the setting of systemic infection remains uncertain with no clear guidelines. We present a unique case of KP in the setting of recurrent septicemia, which required subsequent salvage vertebrectomy.
Case Description: We present a clinical case of a 59-year-old diabetic male patient with a recent foot ulcer, positive for and .
Electromagnetic navigation guided tailored lamino-pedicular intralesional marginal resection of recurrent sacral osteoblastoma: a case report.
J Spine Surg
December 2024
Department of Orthopaedic Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Background: Electromagnetic navigation (EMN) is an advanced technology increasingly utilized in orthopedic surgery for its ability to provide real-time intraoperative guidance. Its application in spinal surgery is evolving rapidly, particularly for complex cases like tumor lesions. Spinal osteoblastomas, characterized by their benign nature, primarily affect the posterior elements of the spine.
View Article and Find Full Text PDFNeurofibromatosis with diffuse intestinal ganglioneuromatosis: a case report.
Transl Cancer Res
December 2024
Department of Pathology, Jieyang People's Hospital, Jieyang, China.
Background: Neurofibromatosis type 1 (NF-1), a rare autosomal dominant disorder, arises from gene mutations affecting neurofibromin, a Ras GTPase regulator. These mutations activate Ras proteins, triggering clinical symptoms such as skin spots, epilepsy, pain, and tumors. Although gastrointestinal stromal tumors are well-known in NF-1, diffuse intestinal ganglioneuromatosis remains an extremely rare complication.
View Article and Find Full Text PDFIRF5 as a potential immunological biomarker in lung adenocarcinoma.
Transl Cancer Res
December 2024
Department of Oncology, Guangzhou First People's Hospital, Guangzhou, China.
Background: In the clinic, the primary conventional treatments of advanced non-small cell lung cancer (NSCLC) are surgery, radiation therapy, and chemotherapy. In recent years, immune checkpoint inhibitors (ICIs) have shown promise in optimizing therapeutic benefits when combined with other immunotherapies or standard therapies. However, effective biomarkers for distant metastasis or recurrence have yet to be identified, making it difficult to determine the best therapeutic approaches.
View Article and Find Full Text PDFMachine learning-based pan-cancer study of classification and mechanism of BRAF inhibitor resistance.
Transl Cancer Res
December 2024
Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Background: V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor (BRAFi) therapy resistance affects approximately 15% of cancer patients, leading to disease recurrence and poor prognosis. The aim of the study was to develop a machine-learning based method to identify patients who are at high-risk of BRAFi resistance and potential biomarker.
Methods: From Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC) databases, we collected RNA sequencing and half maximal inhibitory concentration (IC) data from 235 pan-cancer cell lines and then identified 37 significant differential expression genes associated with BRAFi resistance.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!